Skip to the page

Data / Drug companies / Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC

Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC: 17 products in the FDA NDC directory, labeler code 58394

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC (labeler code 58394) lists 17 products in the FDA National Drug Code Directory, covering 2 finished drugs by generic name. By type: 14 plasma derivatives, 2 drugs for further processing. Its main marketing category is biologics (BLA). The newest product started marketing on September 19, 2019.

The request: Watch Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC (FDA labeler code 58394): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
58394
Products in commercial distribution
17
Packages
17
Finished drugs by generic name
2
Prescription products
0
Over the counter products
0
Started marketing in the last 12 months
0
Earliest marketing start
February 1, 1997
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Biologics (BLA)1482.4%
Drugs for further processing211.8%
Bulk ingredients15.9%

Products by type

TypeProductsShare
Plasma derivatives1482.4%
Drugs for further processing211.8%
Bulk ingredients15.9%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Kit1482.4%
Liquid317.6%

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Bevacizumab58394-095LiquidDrugs for further processingSeptember 19, 2019
Adalimumab58394-051LiquidDrugs for further processingSeptember 19, 2019
BeneFIX58394-637KitBiologics (BLA)February 1, 2012
Xyntha58394-023KitBiologics (BLA)December 1, 2011
Xyntha58394-022KitBiologics (BLA)December 1, 2011
Xyntha58394-025KitBiologics (BLA)August 1, 2011
Xyntha58394-024KitBiologics (BLA)August 1, 2011
Xyntha58394-016KitBiologics (BLA)August 13, 2010
Xyntha58394-015KitBiologics (BLA)August 1, 2008
Xyntha58394-014KitBiologics (BLA)August 1, 2008
Xyntha58394-013KitBiologics (BLA)August 1, 2008
Xyntha58394-012KitBiologics (BLA)August 1, 2008
BeneFIX58394-636KitBiologics (BLA)July 6, 2007
Coagulation factor ix recombinant human58394-789LiquidBulk ingredientsFebruary 1, 1997
BeneFIX58394-635KitBiologics (BLA)February 1, 1997
BeneFIX58394-634KitBiologics (BLA)February 1, 1997
BeneFIX58394-633KitBiologics (BLA)February 1, 1997

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.